ADNT
Adient plc
ADNT has the edge over LCID overall, supported by lower modeled downside.
LCID
Lucid Group, Inc.
LCID offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
ADNT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Stable |
ADNT's revenue, profitability, cash flow and balance sheet are all currently stable.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
ADNT PE Valuation
ADNT has no meaningful PE right now: it lost money over the past year.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
ADNT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect ADNT's earnings to grow, with its revenue and profitability holding steady. However, they disagree widely on these estimates.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
ADNT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.69 | — |
| Q3 2026 | -$0.24 | +$3.15 |
ADNT has the edge over LCID in the latest year-over-year earnings comparison.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
ADNT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +1.1% |
| Q2 2026 | $3.9B | +5% |
| Q1 2026 | $3.9B | +7% |
| Q4 2025 | $3.6B | +4.3% |
ADNT's revenue has grown year over year every quarter since late 2025: $3.7B last quarter, up 1.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 1.6% | -0.1 points |
| Q1 2026 | 2% | +9.3 points |
| Q4 2025 | 1.1% | -0.2 points |
| Q3 2025 | 1.7% | N/A |
| Q2 2025 | 1.8% | N/A |
| Q1 2025 | -7.3% | N/A |
| Q4 2024 | 1.3% | N/A |
ADNT has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over ADNT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
ADNT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $138M | +20% |
| Q1 2026 | $8M | +$98M |
| Q4 2025 | $15M | -67% |
ADNT and LCID do not have enough comparable growth data to identify a winner.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
ADNT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -100K shares |
| 1 year | -5.4% | -4.5M shares |
ADNT has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $30M |
| Q1 2026 | — |
| Q4 2025 | $25M |
| Q3 2025 | $50M |
| Q2 2025 | $50M |
| Q1 2025 | — |
| Q4 2024 | $25M |
ADNT spent $105M buying back its own shares over the past year.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
ADNT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 6.7x | High |
| Q3 2025 | 6.1x | High |
| Q2 2025 | 6.5x | High |
| Q1 2025 | 7.6x | High |
| Q4 2024 | 3.5x | Elevated |
ADNT's net debt is about 2.5 years of its operating earnings (EBITDA), down from 6.5 years a year ago.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ADNT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.6 | Neutral |
| Stochastic | 8.3 | Oversold |
ADNT's weekly RSI is 35 (neutral) and its Stochastic is 8 (oversold).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
ADNT PE vs Consumer Cyclical Sector
| Metric | ADNT | Sector median | Relative |
|---|---|---|---|
| PE | 30x | 18x | 68% above |
| PE % | 59 | 47 | 12 pts above |
ADNT has no meaningful PE right now: it lost money over the past year.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
ADNT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.0 | 6.8% below |
| 20 week MA | $18.6 | 15% below |
| 50 week MA | $20.3 | 22% below |
| 100 week MA | $19.5 | 19% below |
| 200 week MA | $25.9 | 39% below |
ADNT is in a downtrend: it's below all five of its weekly moving averages, and 39% below its 200-week average.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
ADNT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.3 | $34.6 | +63% |
| 2021 | $34.6 | $46.9 | +36% |
| 2022 | $46.9 | $34.1 | -27% |
| 2023 | $34.1 | $36.4 | +6.8% |
| 2024 | $36.4 | $17.4 | -52% |
| 2025 | $17.4 | $19.5 | +12% |
| 2026 YTD | $19.5 | $15.8 | -19% |
ADNT has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.